Ontology highlight
ABSTRACT:
Methods: 1.5 T CMR was performed in 206 subjects with suspected CA (n?=?100, 49% with unexplained left ventricular (LV) hypertrophy; n?=?106, 51% with blood dyscrasia and suspected light-chain amyloidosis). Patients were randomly assigned to the training (n?=?134, 65%), validation (n?=?30, 15%), and testing subgroups (n?=?42, 20%). Short axis, 2-chamber, 4-chamber late gadolinium enhancement (LGE) images were evaluated by 3 networks (DL algorithms). The tags "amyloidosis present" or "absent" were attributed when the average probability of CA from the 3 networks was???50% or?
Results: The DL strategy displayed good diagnostic accuracy (88%), with an area under the curve (AUC) of 0.982. The precision (positive predictive value), recall score (sensitivity), and F1 score (a measure of test accuracy) were 83%, 95%, and 89% respectively. A ML algorithm considering all CMR features had a similar diagnostic yield to DL strategy (AUC 0.952 vs. 0.982; p?=?0.39).
Conclusions: A DL approach evaluating LGE acquisitions displayed a similar diagnostic performance for CA to a ML-based approach, which simulates CMR reading by experienced operators.
SUBMITTER: Martini N
PROVIDER: S-EPMC7720569 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Martini Nicola N Aimo Alberto A Barison Andrea A Della Latta Daniele D Vergaro Giuseppe G Aquaro Giovanni Donato GD Ripoli Andrea A Emdin Michele M Chiappino Dante D
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20201207 1
<h4>Background</h4>Cardiovascular magnetic resonance (CMR) is part of the diagnostic work-up for cardiac amyloidosis (CA). Deep learning (DL) is an application of artificial intelligence that may allow to automatically analyze CMR findings and establish the likelihood of CA.<h4>Methods</h4>1.5 T CMR was performed in 206 subjects with suspected CA (n = 100, 49% with unexplained left ventricular (LV) hypertrophy; n = 106, 51% with blood dyscrasia and suspected light-chain amyloidosis). Patients we ...[more]